ANDA 75574, held by Actavis Elizabeth. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75574 (Doxazosin Mesylate), held by Actavis Elizabeth, was first approved by FDA on Oct 18, 2000, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Oct 31, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Feb 4, 2004 | Supplement 5Labeling | Approved | None posted |
| Oct 22, 2002 | Supplement 3Labeling | Approved | None posted |
| Nov 2, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Jun 21, 2001 | Supplement 1Labeling | Approved | None posted |
| Oct 18, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters